Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Non-Controlling Interests (2016 - 2018)

Historic Income from Non-Controlling Interests for Coherus Oncology (CHRS) over the last 5 years, with Q3 2018 value amounting to -$18000.0.

  • Coherus Oncology's Income from Non-Controlling Interests fell 35000.0% to -$18000.0 in Q3 2018 from the same period last year, while for Jun 2019 it was -$18000.0, marking a year-over-year increase of 6896.55%. This contributed to the annual value of -$70000.0 for FY2018, which is 3965.52% up from last year.
  • As of Q3 2018, Coherus Oncology's Income from Non-Controlling Interests stood at -$18000.0, which was down 35000.0% from -$47000.0 recorded in Q2 2018.
  • Coherus Oncology's Income from Non-Controlling Interests' 5-year high stood at $111000.0 during Q4 2014, with a 5-year trough of -$224000.0 in Q2 2015.
  • Its 5-year average for Income from Non-Controlling Interests is -$75500.0, with a median of -$56500.0 in 2017.
  • As far as peak fluctuations go, Coherus Oncology's Income from Non-Controlling Interests soared by 9578.95% in 2017, and later crashed by 35000.0% in 2018.
  • Coherus Oncology's Income from Non-Controlling Interests (Quarter) stood at $111000.0 in 2014, then plummeted by 270.27% to -$189000.0 in 2015, then soared by 87.83% to -$23000.0 in 2016, then skyrocketed by 91.3% to -$2000.0 in 2017, then tumbled by 800.0% to -$18000.0 in 2018.
  • Its Income from Non-Controlling Interests stands at -$18000.0 for Q3 2018, versus -$47000.0 for Q2 2018 and -$5000.0 for Q1 2018.